Compare JetBlue Airways Corporation (JBLU) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JetBlue Airways Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? JetBlue Airways Corporation trades at $5.34 (market cap $2.03B), while State Street SPDR S&P Biotech ETF trades at $154.37. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, JetBlue Airways Corporation nearer its low. Which is the better fit depends on your goals.
| JBLU | XBI | |
|---|---|---|
Market Cap | $2.03B | — |
Sector | Industrials | Broad Market / Factor |
52-Week High | $6.46 | $164.28 |
52-Week Low | $4.03 | $85.16 |
Enterprise Value | $9.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JetBlue (JBLU) trades at $5.35, down 1.29% on the day, with mixed technical signals showing a neutral overall bias. The company faces fundamental challenges with negative profitability metrics, including a -7.78% net income margin and -33.51% ROE, despite reasonable valuation ratios like P/S of 0.22. Recent developments include securing Spirit Airlines' LaGuardia Airport slots and launching new payment partnerships, providing potential operational catalysts amid ongoing losses.
The outlook remains challenging with persistent net losses and high debt levels, though strategic expansions and new financing options offer growth potential. Key risks include fuel cost volatility and competitive pressures, while analyst sentiment is cautious with a $5.12 consensus target suggesting limited upside from current levels.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
